Interferon-γ–Dependent Infiltration of Human T Cells into Neuroblastoma Tumors In vivo

Purpose: To investigate the impact of interferon-γ–mediated upregulation of major histocompatibility complex class I expression on tumor-specific T-cell cytotoxicity and T-cell trafficking into neuroblastoma tumors in vivo . Experimental Design: Restoration of major histocompatibility complex cla...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical cancer research 2009-11, Vol.15 (21), p.6602
Hauptverfasser: Gregor S.D. Reid, Xiaochuan Shan, Christina M. Coughlin, Wiem Lassoued, Bruce R. Pawel, Leonard H. Wexler, Carol J. Thiele, Maria Tsokos, Jack L. Pinkus, Geraldine S. Pinkus, Stephan A. Grupp, Robert H. Vonderheide
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose: To investigate the impact of interferon-γ–mediated upregulation of major histocompatibility complex class I expression on tumor-specific T-cell cytotoxicity and T-cell trafficking into neuroblastoma tumors in vivo . Experimental Design: Restoration of major histocompatibility complex class I expression by interferon-γ treatment enhances killing of neuroblastoma cells. To understand the potential of this approach in vivo , we developed a novel model of neuroblastoma in which NOD/ scid / IL2Rγ null immunodeficient mice are engrafted with both human T cells and tumor cells. Results: Here, we show enhanced killing of neuroblastoma cells by patient-derived, tumor-specific T cells in vitro . In addition, interferon-γ treatment in vivo induces efficient upregulation of major histocompatibility complex class I expression on neuroblastoma tumor cells, and this is accompanied by significantly enhanced infiltration of T cells into the tumor. In a pilot clinical trial in patients with high-risk neuroblastoma, we similarly observed augmented T-cell trafficking into neuroblastoma nests in tumor biopsy specimens obtained from patients after 5 days of systemic interferon-γ therapy. Conclusions: Interferon-γ overcomes critical obstacles to the killing of human neuroblastoma cells by specific T cells. Together, these findings provide a rationale for the further testing of interferon-γ as an approach for improving the efficacy of T cell–based therapies for neuroblastoma and other major histocompatibility complex class I–deficient malignancies. In addition, we describe a model that may expedite the preclinical screening of approaches aimed at augmenting T-cell trafficking into human tumors. (Clin Cancer Res 2009;15(21):6602–8)
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-09-0829